Publicacións en colaboración con investigadores/as de University of Leeds (23)

2024

  1. Risk loci involved in giant cell arteritis susceptibility: a genome-wide association study

    The Lancet Rheumatology, Vol. 6, Núm. 6, pp. e374-e383

2022

  1. Intra-articular therapies: patient preferences and professional practices in European countries

    Rheumatology International, Vol. 42, Núm. 5, pp. 869-878

2021

  1. EULAR recommendations for intra-articular therapies

    Annals of the Rheumatic Diseases, Vol. 80, Núm. 10, pp. 1299-1305

  2. Efficacy and safety of intra-articular therapies in rheumatic and musculoskeletal diseases: An overview of systematic reviews

    RMD Open, Vol. 7, Núm. 2

2019

  1. EULAR points to consider for the development, evaluation and implementation of mobile health applications aiding self-management in people living with rheumatic and musculoskeletal diseases

    RMD Open, Vol. 5, Núm. 2

2017

  1. A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis

    American Journal of Human Genetics, Vol. 100, Núm. 1, pp. 64-74

  2. EULAR/PReS standards and recommendations for the transitional care of young people with juvenile-onset rheumatic diseases

    Annals of the Rheumatic Diseases, Vol. 76, Núm. 4, pp. 639-646

2016

  1. Evidence for treating rheumatoid arthritis to target: Results of a systematic literature search update

    Annals of the Rheumatic Diseases, Vol. 75, Núm. 1, pp. 16-22

2015

  1. A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility

    American Journal of Human Genetics, Vol. 96, Núm. 4, pp. 565-580

  2. Development of patient-centred standards of care for osteoarthritis in Europe: The eumusc.net-project

    Annals of the Rheumatic Diseases, Vol. 74, Núm. 6, pp. 1145-1149

2014

  1. Tocilizumab-induced psoriasiform rash in rheumatoid arthritis

    Dermatology, Vol. 228, Núm. 4, pp. 311-313

2013

  1. Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: Systematic literature review and meta-analysis informing a consensus statement

    Annals of the Rheumatic Diseases, Vol. 72, Núm. 4, pp. 583-589

  2. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions

    Annals of the Rheumatic Diseases, Vol. 72, Núm. 4, pp. 482-492

2011

  1. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials

    Annals of the Rheumatic Diseases, Vol. 70, Núm. 3, pp. 404-413

  2. American college of rheumatology/European league against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials

    Arthritis and Rheumatism, Vol. 63, Núm. 3, pp. 573-586

  3. Linear pitting and splinter haemorrhages are more commonly seen in the nails of patients with established psoriasis in comparison to psoriatic arthritis

    Dermatology, Vol. 223, Núm. 4, pp. 370-373

  4. Treating rheumatoid arthritis to target: Multinational recommendations assessment questionnaire

    Annals of the Rheumatic Diseases, Vol. 70, Núm. 11, pp. 1999-2002

2010

  1. The Eular recommendations for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs

    Rheumatologia, Vol. 24, Núm. 4, pp. 143-158

  2. Treating rheumatoid arthritis to target: Recommendations of an international task force

    Annals of the Rheumatic Diseases, Vol. 69, Núm. 4, pp. 631-637

2008

  1. Methods of deriving EULAR/ACR recommendations on reporting disease activity in clinical trials of patients withd-heumatoid arthritis

    Annals of the Rheumatic Diseases, Vol. 67, Núm. 10, pp. 1365-1373